288 related articles for article (PubMed ID: 3708573)
1. Therapeutic synergism of tiazofurin and selected antitumor drugs against sensitive and resistant P388 leukemia in mice.
Harrison SD; O'Dwyer PJ; Trader MW
Cancer Res; 1986 Jul; 46(7):3396-400. PubMed ID: 3708573
[TBL] [Abstract][Full Text] [Related]
2. Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia.
Waud WR; Harrison SD; Gilbert KS; Laster WR; Griswold DP
Cancer Chemother Pharmacol; 1991; 27(6):456-63. PubMed ID: 1849465
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic synergy of trimetrexate (CI-898) in combination with doxorubicin, vincristine, cytoxan, 6-thioguanine, cisplatin, or 5-fluorouracil against intraperitoneally implanted P388 leukemia.
Leopold WR; Dykes DJ; Griswold DP
NCI Monogr; 1987; (5):99-104. PubMed ID: 2963231
[TBL] [Abstract][Full Text] [Related]
4. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Borden EC; Sidky YA; Hatcher JF; Bryan GT
Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
[TBL] [Abstract][Full Text] [Related]
5. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.
Li LH; DeKoning TF; Wallace TL
Cancer Res; 1987 Nov; 47(22):5894-900. PubMed ID: 3664490
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro studies of Tiazofurin and a selenazole analog.
Streeter DG; Robins RK
Biochem Biophys Res Commun; 1983 Sep; 115(2):544-50. PubMed ID: 6138036
[TBL] [Abstract][Full Text] [Related]
7. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
Ardalan B; Jayaram HN; Johnson RK
Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
[TBL] [Abstract][Full Text] [Related]
8. [Experimental combination chemotherapy of YNK01, a novel analog of cytarabine, with other antitumor agents].
Uchida T; Nagahata T; Arakawa M; Ekimoto H; Takahashi K
Gan To Kagaku Ryoho; 1990 Jul; 17(7):1351-6. PubMed ID: 2114829
[TBL] [Abstract][Full Text] [Related]
9. [Combined effect of CDDP with various types of antitumor drugs against P 388 leukemia].
Uchida T; Nishikawa K; Shibasaki C; Okamoto K; Arakawa M; Ekimoto H; Takahashi K
Gan To Kagaku Ryoho; 1989 Jun; 16(6):2275-82. PubMed ID: 2735770
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
[TBL] [Abstract][Full Text] [Related]
11. cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.
Schabel FM; Trader MW; Laster WR; Corbett TH; Griswold DP
Cancer Treat Rep; 1979; 63(9-10):1459-73. PubMed ID: 291480
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
Tsuruo T; Oh-Hara T; Sudo Y; Naito M
Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and therapeutic efficacy of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388.
Avramis VI; Plunkett W
Cancer Res; 1982 Jul; 42(7):2587-91. PubMed ID: 7083151
[TBL] [Abstract][Full Text] [Related]
14. The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF/CEM/0 and (CCRF/CEM/ara-C/7A) is due to increased cellular apoptosis.
Nandy P; Periclou AP; Avramis VI
Anticancer Res; 1998; 18(2A):727-37. PubMed ID: 9615712
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin combined with the new cisplatin-procaine complex DPR: in vitro and in vivo studies.
Viale M; Vannozzi MO; Merlo F; Cafaggi S; Parodi B; Esposito M
Eur J Cancer; 1996 Dec; 32A(13):2327-33. PubMed ID: 9038617
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
17. [Effects of combination chemotherapy of MCNU with various anti-cancer agents].
Machida S; Ito Y; Hoshino A
Gan To Kagaku Ryoho; 1985 Feb; 12(2):298-302. PubMed ID: 3918506
[TBL] [Abstract][Full Text] [Related]
18. 1-beta-D-arabinofuranosylcytosine conjugates of thioether phospholipids as a new class of potential antitumor drugs.
Hong CI; Kirisits AJ; Buchheit DJ; Nechaev A; West CR
Cancer Drug Deliv; 1986; 3(2):101-13. PubMed ID: 3708534
[TBL] [Abstract][Full Text] [Related]
19. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide--V. Factors governing the response of murine tumors to tiazofurin.
Ahluwalia GS; Jayaram HN; Plowman JP; Cooney DA; Johns DG
Biochem Pharmacol; 1984 Apr; 33(8):1195-203. PubMed ID: 6143562
[TBL] [Abstract][Full Text] [Related]
20. Biochemical mechanisms of resistance to tiazofurin.
Jayaram HN
Adv Enzyme Regul; 1985; 24():67-89. PubMed ID: 3835825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
